ASMI supports TGA Review of Complementary Medicines
7 April 2014 - The Australian Self Medication Industry (ASMI) today said that the Therapeutic Goods Administration (TGA) is to be acknowledged for publishing, for the first time, its annual review of complementary medicines.
Each year the TGA reviews a proportion of listed complementary medicines to check for compliance with regulatory requirements. The TGA undertakes the review at any time after a product is listed in the Australian Register of Therapeutic Goods (ARTG). During the review the TGA asks to see any information a sponsor has to verify the certifications they have made. If that certification is incorrect, the TGA then considers taking regulatory action.
The TGA varies the proportion of random and targeted reviews to ensure the risk benefit approach is maintained. The TGA's aim is to increase compliance through education and these review processes.
Steve Scarff, ASMI Director of Regulatory and Scientific
Affairs, said that ASMI supports the TGA's review approach and the
publication of its review findings. "Regulations are in place to
protect public health and safety and it is critical that sponsors
comply with them. If a sponsor does not comply with the regulations
the TGA should take action.
"It is good to see that the TGA has a transparent mechanism in place to assess and report compliance and that it takes action in cases of non-compliance," said Mr Scarff.
About ASMI: The Australian Self-Medication Industry (ASMI) is the peak body representing sponsors of non-prescription medicines - over-the-counter (OTC) and complementary medicines. Its members make up 85 per cent of the $4bn self care market. Membership totals 60 companies and ASMI members employ approximately 17,000 people with exports estimated at $600 million annually. ASMI's mission is to promote better health through responsible self care. This means ensuring that safe and effective self care products are readily available to all Australians at a reasonable cost. ASMI works to encourage responsible use by consumers and an increasing role for cost-effective self-medication products as part of the broad national health strategy (www.asmi.com.au).
For more information or to arrange a media interview, please
PR Manager, Australian Self Medication Industry (ASMI)
P: 9923 9410 M:0408 256 381 E: email@example.com